Cipla said that it has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co. for Rolditamig Deuderuxtecan, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.